Cephalon, Inc. is a U.S. biopharmaceutical company co-founded in 1987 by Dr. Frank Baldino, Jr., a pharmacologist and former scientist with the DuPont Company, who served as the company's chairman and chief executive officer until his death in December 2010. The company's name comes from the adjective "cephalic" meaning "related to the head or brain," and it was established primarily to pursue treatments for neurodegenerative diseases.Sales revenues reached $2.8 billion in 2010, ranking Cephalon among the leading biopharmaceutical companies in the world. In 2006, industry publication MedAd News named the company one of the ten most respected biotechnology firms in the world. Cephalon employs more than 3,700.Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.On 2 May 2011, Teva announced its acquisition of Cephalon. Wikipedia.
Cephalon Inc. | Date: 2014-02-10
Cephalon Inc. | Date: 2014-11-03
Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
Cephalon Inc. | Date: 2015-09-04
The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
Cephalon Inc. | Date: 2015-08-12
The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
Cephalon Inc. | Date: 2014-05-13
The present application provides compounds of Formula I or salt forms thereof, wherein R